Historically a steel production hub, Lehigh Valley will now help manufacture Lilly’s weight loss drug hopeful retatrutide.

Kyowa Kirin will now file for rocatinlimab’s US approval in atopic dermatitis (AD), which was once Amgen’s most late-stage pipeline candidate.

The California Institute for Regenerative Medicine has approved the RAPID funding programme, setting aside $100m over two ...

Johnson & Johnson has received a positive opinion from the EMA CHMP and recommended an indication extension for Akeega .

Repertoire Immune Medicines has collaborated with Eli Lilly for the development of tolerising therapies to treat several ...

This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...

The FDA has granted breakthrough therapy designation to Biogen’s litifilimab for CLE, a chronic autoimmune skin condition.

The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline ...

AstraZeneca has returned to CSPC with a licensing deal for the Chinese company’s monthly injectables for obesity.

The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.

Sanofi's sales grew 9.9% YoY – driven by a diverse range of portfolio classics and new launches across immunology, oncology and rare disease.